Publication at Faculty of Medicine in Hradec Králové |
2021
Abstract
Multiple sclerosis is a chronic inflammatory demyelinating disease which affect central nervous system. Treatment options for multiple sclerosis have expanded significantly in recent years.The drug portfolio now includes ofatumumab.
Ofatumumab, is a fully human monoclonal antibody against CD20 antigen. This drug has significant anti-inflammatory effect, reduce the number of relapses, and also has positive effect on radiological parameters.